Eli Lilly's Earnings Beat Was Big. What Options Traders Had Priced In Tells the Real Story

A Beat-and-Raise Quarter, Priced In Advance

Eli Lilly (NYSE: LLY) reported second-quarter 2026 results before the market opened on August 5, 2026, and the numbers were emphatic: revenue of roughly $23.0 billion, above Wall Street's expectations, and adjusted earnings per share of $8.38 (also beating estimates, which had ranged from about $6.01 to $6.71 across various data providers ahead of the print). Mounjaro — Lilly's GLP-1 diabetes drug, part of a class of medications that mimics a gut hormone to regulate blood sugar and appetite — posted worldwide revenue of $9.9 billion, up 91% year over year, while Zepbound, its weight-loss counterpart, grew U.S. revenue 44% to $4.9 billion. Lilly raised its full-year revenue guidance to $85 billion–$87 billion, up from a prior $82 billion–$85 billion range.

Shares moved sharply higher on the news. Against Tuesday's $1,115.68 close, Lilly opened Wednesday at $1,174.00 — already up about 5.2% — and touched an intraday high of $1,216.94, or roughly 9% above the prior close, before settling back somewhat from that peak. Even that range depends on exactly when you check the tape: one wire headline framed it as a "6% surge," while the open-versus-prior-close math gets you closer to 5%. That's a useful reminder before we get to the lesson: even "the stock's reaction" isn't a single clean number — it depends on the exact moment measured.

But the more interesting story, for options traders, isn't what Lilly did — it's what the options market had already bet it would do.

What "Implied Move" Actually Means

Ahead of any known, dated event like an earnings report, options prices embed a market forecast of how far the stock is likely to move — up or down — once the news is out. That forecast is called the "implied move," and it isn't guesswork by any single analyst; it's derived mechanically from the price of options themselves.

Here's the shortcut version of the math: take the nearest-expiration at-the-money call (a bet the stock rises above a set price) and the at-the-money put (a bet it falls below one) — the pair expiring just after the event — add their prices together to get the "straddle" price, then multiply by roughly 0.85 to correct for a straddle typically overstating a one-standard-deviation range (statistically, the band a stock is expected to stay within about two-thirds of the time). Divide that dollar number by the stock price, and you get a percentage — the implied move.

In the days ahead of Lilly's report, that number moved. A lot. Benzinga's options-data desk pegged the implied move at 7.37% (about $76.4 billion of Lilly's roughly $1.04 trillion market cap) in an article published the morning of August 3. One day later, a separate Benzinga piece — citing the same data provider — put it at 6.56% (about $65.9 billion on a slightly lower market cap). A third source, Investing.com, had it at 6.9%.

None of these figures is "wrong." They're snapshots of a number that moves continuously as new options trades happen, right up until the contracts stop trading ahead of the print. That's the first real lesson here: the "implied move" quoted in a headline is a moving target, not a fixed prediction, and a number from three days before earnings can be meaningfully stale by the morning of the report.

Reality vs. What Was Priced In

So how did the roughly 6.5%–7.4% range priced in ahead of the print compare to what actually happened? Lilly's move — somewhere between about 5% at the open and roughly 9% at its intraday high — landed at or above the top of what options markets had priced in, not comfortably inside it. In other words, this was one of the less common cases where the realized move actually exceeded the implied move: a beat-and-raise quarter large enough to blow through the range option sellers had been compensated for.

That's the less common outcome, and it's instructive precisely because it's less common. Implied move is a probabilistic estimate — roughly analogous to a one-standard-deviation range — meaning the stock is expected to land inside that band more often than not, but "more often than not" still leaves room for the tail event where a print is significant enough to move the stock beyond what any straddle price had anticipated. When that happens, traders who bought options and correctly called the direction can come out ahead even after IV crush, because the size of the move outweighs the collapse in volatility premium — the flip side of the more common scenario where a move lands inside the priced-in range and IV crush dominates regardless of direction.

The Part That Actually Costs Traders Money: IV Crush

Here's where a lot of options buyers get hurt even when they're directionally right. Implied volatility — the "IV" in IV crush — is the ingredient that inflates options premiums ahead of a known catalyst like earnings. Once the news is out and the uncertainty resolves, that volatility premium tends to collapse almost immediately, often within the first trading session, sometimes within the first hour. That collapse can strip a meaningful chunk of an option's value overnight, even if the stock moved in the direction a trader correctly guessed — because the loss from evaporating volatility premium can outweigh the gain from a correct directional call, especially for short-dated contracts (options with little time left before expiration).

For a stock like Lilly, where the realized move actually landed at or beyond the top of the priced-in range, the dynamic flips: a large enough directional move can outrun IV crush, letting correctly-directional option buyers profit despite the volatility collapse. But that's precisely why this print is useful as a teaching example rather than a rule to bank on — most earnings reports don't produce a move large enough to overcome IV crush, and there's no way to know in advance which report will be the exception.

The Takeaway

Eli Lilly's Q2 print is a clean, real-world example of three mechanics every options trader should internalize. First, implied move is calculated from options prices themselves and updates continuously — it's not a fixed forecast. Second, a stock landing "within" its priced-in range is the statistically expected outcome, though not a guarantee: Lilly's own move this week landed at or beyond the top of that range, a reminder that the tail scenario happens too. Third, IV crush usually matters more than direction for anyone holding options purely for earnings-day volatility — except in exactly this kind of outsized-move scenario, which is impossible to identify in advance.

None of this is a comment on whether Lilly stock is a good investment — Mounjaro and Zepbound's growth rates are a separate question from how options around the print were priced. Options trading carries substantial risk of loss, including the potential to lose the entire premium paid, and isn't suitable for every investor.

This article is educational commentary on public market events, not personalized investment, trading, or tax advice.